Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers

Junjie Chen, Shenmeng Gao, Chunjing Wang, Zhonggai Wang, Huxiang Zhang, Kate Huang, Bin Zhou, Haiying Li, Zhijie Yu, Jianbo Wu, Chengshui ChenJournal of Experimental & Clinical Cancer Research 2016 · DOI

TL;DR

This study reveals that a microRNA, miR-193a, is significantly downregulated in non-small cell lung cancer (NSCLC) and its reduced expression promotes metastasis and epithelial-mesenchymal transition (EMT). The researchers identified a novel pathway where miR-193a targets WT1, which in turn regulates E-cadherin, suggesting a potential therapeutic strategy of restoring miR-193a levels.

What Problem Does This Paper Address?

Lung cancer remains a leading cause of cancer-related deaths, with metastasis being the primary driver of mortality. While the metastatic cascade is complex, epithelial-mesenchymal transition (EMT) is a critical process enabling cancer cells to detach, invade, and spread. Identifying molecular players that regulate EMT and metastasis is crucial for developing effective treatments. Previous research suggested miR-193a as a tumor suppressor, but its specific role and underlying mechanisms in NSCLC metastasis were not fully understood. This paper aims to elucidate the function of miR-193a in NSCLC metastasis and EMT, focusing on its potential targets and therapeutic implications.

Methods

The researchers employed a multi-pronged approach to investigate miR-193a's role:

  • Expression Analysis: Real-time PCR was used to quantify miR-193a levels in NSCLC tissues and cell lines, comparing them to normal counterparts.
  • Mechanism of Regulation: Methylation-specific PCR (MSP) and treatment with a DNA methyltransferase inhibitor (5'-azacytidine) were used to explore if DNA hypermethylation contributed to miR-193a downregulation.
  • Functional Assays:
    • Cell Proliferation: CCK-8 assays were used to measure cell growth.
  • Apoptosis: Flow cytometry was employed to assess cell death.
  • Migration and Invasion: Transwell assays were utilized to evaluate the ability of cells to move and penetrate barriers.
  • Wound Healing: Assays were performed to assess cell migration.
  • Colony Formation: Assays measured the ability of cells to form colonies.
  • Target Identification: Dual-luciferase reporter assays were used to confirm direct targeting of WT1 by miR-193a.
  • Protein and Gene Expression: Western blotting and qRT-PCR were used to assess protein and mRNA levels of key molecules like WT1 and E-cadherin.
  • Immunofluorescence and Immunohistochemistry: These techniques were used to visualize the localization and expression of proteins in cells and tissues.
  • In Vivo Studies: Tumorigenicity was assessed in nude mice xenograft models.

Datasets

The study utilized:

  • Human NSCLC Tissues: 62 paired lung cancer specimens and adjacent non-tumor tissues were collected.
  • NSCLC Cell Lines: Several NSCLC cell lines (A549, H1299, etc.) and a normal lung epithelial cell line (BEAS-2B) were used.
  • Animal Models: Nude mice were used for xenograft tumor growth experiments.

Key Insights and Ideas

  • miR-193a as a Metastasis Suppressor in NSCLC: The study provides strong evidence that miR-193a acts as a tumor suppressor in NSCLC, with its downregulation correlating with increased metastasis.
  • WT1 as a Direct Target of miR-193a: The research identifies Wilms tumor 1 (WT1) as a direct molecular target of miR-193a, establishing a novel regulatory axis.
  • The miR-193a-WT1-E-cadherin Axis: A key finding is the proposed pathway where miR-193a suppresses WT1, which in turn negatively regulates E-cadherin. This axis is central to controlling EMT and metastasis.
  • DNA Hypermethylation Silences miR-193a: The study demonstrates that DNA hypermethylation is a significant mechanism leading to the reduced expression of miR-193a in NSCLC.
  • miR-193a Counteracts TGF-β1-Induced EMT: The research shows that miR-193a can partially reverse the EMT process induced by TGF-β1, a known inducer of metastasis.
  • WT1's Oncogenic Role in Metastasis: The study highlights WT1's role in promoting NSCLC metastasis, as its knockdown mimicked miR-193a's anti-metastatic effects, and its overexpression partially reversed these effects.

Key Results

  • Downregulation of miR-193a: miR-193a expression was significantly reduced in 81% of NSCLC tissues and in lung cancer cell lines compared to normal controls. This downregulation was linked to advanced stages and the presence of metastasis.
  • Inhibition of Metastasis by miR-193a: Overexpression of miR-193a in NSCLC cells significantly reduced migration, invasion, wound healing, colony formation, and cell proliferation.
  • WT1 Targeting: Luciferase assays confirmed that miR-193a directly targets WT1.
  • WT1 and E-cadherin Regulation: miR-193a overexpression led to decreased WT1 protein levels and increased E-cadherin expression. Conversely, WT1 knockdown reduced migration and invasion, while WT1 overexpression partially reversed miR-193a's anti-metastatic effects.
  • EMT Reversal: Overexpression of miR-193a partially prevented TGF-β1-induced EMT, as evidenced by changes in E-cadherin, fibronectin, and vimentin expression.
  • Tumor Growth Inhibition: In vivo studies showed that tumors formed by cells overexpressing miR-193a were significantly smaller and grew slower than control tumors.

Limitations and Future Work

  • Multiple Targets of miR-193a: While WT1 is identified as a key target, the paper acknowledges that miR-193a may have other mRNA targets that also contribute to carcinogenesis and metastasis. Further investigation into these additional targets is warranted.
  • WT1 Isoforms: The study notes that WT1 has multiple isoforms, and the specific role of each isoform in lung cancer metastasis remains largely unknown. Future research could explore isoform-specific functions.
  • Therapeutic Strategy: The findings suggest restoring miR-193a expression or decreasing WT1 expression as potential therapeutic strategies. Further preclinical and clinical studies would be needed to validate these approaches.
  • Mechanism of TGF-β1-induced miR-193a Decrease: While the study shows TGF-β1 reduces miR-193a expression, the precise underlying mechanism requires further elucidation.

Summary updated

Abstract

Collectively, our results have revealed an important role of miR-193a-WT1-E-cadherin axis in metastasis, demonstrated an important molecular cue for EMT, and suggested a therapeutic strategy of restoring miR-193a expression in NSCLC.
BibTeX
@article{chen2016pathologically,
  author = {Junjie Chen and Shenmeng Gao and Chunjing Wang and Zhonggai Wang and Huxiang Zhang and Kate Huang and Bin Zhou and Haiying Li and Zhijie Yu and Jianbo Wu and Chengshui Chen},
  title = {{Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2016},
  doi = {10.1186/s13046-016-0450-8},
}
Figure